Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01012817
Show Display Options
Rank Status Study
1 Suspended Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Conditions: Adult Solid Neoplasm;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Veliparib;   Drug: Topotecan Hydrochloride;   Other: Pharmacogenomic Study;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis

Indicates status has not been verified in more than two years